Meningococcal Vaccine Market Update

UNICEF procures Meningococcal Vaccines for 4 programmatic uses

- Routine immunization programmes (MenA conjugate)
- Preventive immunization campaigns (MenA conjugate)
- Outbreak response (serogroup A, C, W, polysaccharide and conjugate)
- Travelers (serogroup A, C, Y, W, polysaccharide and conjugate)

The supply market for vaccines containing the serogroups A, C, W, PS/Conj. is significantly different to MenA Conj. vaccine and UNICEF therefore employs different strategies in each.
MenA Conj. Vaccine Market Update

Supply is sufficient to satisfy demand
One supplier market

Forecasting accuracy improving
Projecting the timing of catch-up campaigns remains a challenge
10 countries have introduced

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mening A Conj (5 mcg)</td>
<td>5,284,000</td>
<td>6,571,500</td>
<td>23,118,700</td>
<td>2,382,800</td>
<td>21,150,000</td>
<td>22,000,000</td>
<td></td>
</tr>
<tr>
<td>Mening A Conj (10 mcg)</td>
<td>46,752,900</td>
<td>30,651,500</td>
<td>9,189,500</td>
<td>46,043,300</td>
<td>4,500</td>
<td>3,150,000</td>
<td>0</td>
</tr>
<tr>
<td>Mening A Conj (10 mcg) - Emergency stockpile</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,500,000</td>
<td>1,500,000</td>
<td>1,500,000</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>46,752,900</td>
<td>35,935,500</td>
<td>15,761,000</td>
<td>69,162,000</td>
<td>3,887,300</td>
<td>25,800,000</td>
<td>23,500,000</td>
</tr>
</tbody>
</table>
MenA Conj. Vaccine Market Update

GAVI Vaccine Investment Strategy included Multivalent Meningococcal Conjugate, subject to funding and availability of affordable vaccine.

SAGE is reviewing the programme recommendation for use of Meningococcal vaccine – position expected by October 2020.
Meningococcal ACW – Emergency Stockpile

Access to Meningococcal C/W containing vaccines for the Emergency Stockpile remains constrained.

The limited available quantities of quality assured multivalent conjugate vaccines are expensive.

UNICEF is employing special contracting terms to ensure access to available vaccines, but is working with suppliers to identify risk sharing modalities.

The International Coordinating Group (ICG) for Meningococcal Vaccine, established the Stockpile need for 2020:

- 5 million doses C/W containing
  - of which 3 million doses W cont.
- 1.5 million doses MenA Conj
UNICEF is inviting Meningococcal vaccine manufacturers to re-examine their ability to make vaccines available.

UNICEF is seeking access to additional 2 million doses for the emergency stockpile for the 2020 epidemic season.
Meningococcal Vaccine Market Update – Next Steps

Men A Conj. Vaccine
Finalize extension of LTAs for MenA Vaccine supply through 2021

Emergency Stockpile
Engage suppliers to ensure stockpile is replenished for epidemic seasons 2020/21

Tender issuance projected Q1 2021 for supply 2022+
UNICEF
for every child

THANK YOU